sedation: nootropics and compounds | sci-wiki

Alfaxalone

Alfaxalone (also spelled alphaxalone) is a synthetic neuroactive steroid of the pregnane class that produces general anesthesia by acting as a positive allosteric modulator (a molecule that amplifies a receptor's response to its own neurotransmitter) at the GABA-A receptor, the principal inhibitory ion channel of the central nervous system. First introduced in 1971 as the main active component of the intravenous anesthetics Althesin (human) and Saffan (veterinary), it was withdrawn from human use in the 1980s because the solubilizing vehicle Cremophor EL provoked anaphylactoid reactions, then reintroduced in a cyclodextrin formulation marketed for veterinary anesthesia as Alfaxan. Because it lacks classical hormonal activity yet retains rapid, non-cumulative central depressant effects, alfaxalone occupies a distinct pharmacological niche among intravenous anesthetics and now serves as a template for a new generation of water-soluble neurosteroid sedatives such as Phaxan.

reference

Anesthetic

Alphadolone

Alphadolone (alfadolone; clinically alphadolone acetate) is a synthetic neuroactive pregnane steroid (a laboratory-made steroid that acts on the nervous system) which potentiates the GABA-A receptor, the brain's principal fast inhibitory chloride channel, to produce sedation and anaesthesia. It is best known as the minor component of the intravenous anaesthetic Althesin (for humans) and Saffan (for animals), where it was combined with the more potent alfaxalone in a 3:1 ratio, added chiefly to improve the poor water solubility of alfaxalone while still contributing roughly half of that agent's anaesthetic potency in its own right. Both preparations were dissolved in the surfactant Cremophor EL, whose tendency to trigger histamine release and anaphylactoid reactions led to the withdrawal of Althesin from human use in 1984. Alphadolone later attracted independent research interest because, unlike alfaxalone, it produces spinally mediated analgesia without sedation when given by mouth or intraperitoneally, an effect thought to depend on an analgesic metabolite formed in the liver.

reference

NMDA Modulator

Aptiganel

Aptiganel (originally CNS-1102, later tested under the name Cerestat) was one of the most closely watched NMDA-antagonist neuroprotectants of the 1990s, developed by Cambridge NeuroScience to fight acute ischemic stroke. The logic was straightforward and, at the time, compelling: strokes trigger a flood of glutamate that overactivates NMDA receptors and kills neurons through excitotoxicity, so blocking the channel early should limit the damage. It reached large Phase III trials, but the pivotal study (published in JAMA in 2001) was stopped for futility, showing no benefit over placebo while producing hallucinations, agitation, and blood pressure spikes at the doses needed for neuroprotection. Aptiganel became one of the signature failures cited in the broader post-mortem on why NMDA-antagonist neuroprotection never worked clinically for stroke, despite decades of strong animal data.

reference

Dissociative

Gacyclidine

Gacyclidine (GK-11) is a phencyclidine derivative built for an entirely different job than PCP or ketamine ever had: not anesthesia or recreational dissociation, but neuroprotection after acute spinal cord injury. French chemist Jean-Marie Kamenka's PCP-analog work fed into development by Beaufour-Ipsen through the 1990s, producing a compound with roughly 100x higher affinity than PCP itself at the same NMDA channel binding site. It moved into human testing for acute spinal cord injury and was also explored for protecting the inner ear during cochlear trauma, while French defense-affiliated researchers separately studied it as a possible countermeasure for nerve-agent-induced seizures. Development for CNS trauma quietly stalled in the early 2000s as the whole NMDA-antagonist neuroprotectant class collapsed under disappointing trial results and psychotomimetic side effects, leaving gacyclidine as one of the more unusual dead ends in the ketamine/PCP family tree.

reference

Anesthetic

Hydroxydione

Hydroxydione is a synthetic pregnane neuroactive steroid that, introduced by Pfizer in 1955 under the trade name Viadril (also Presuren), became the first steroid used as an intravenous general anesthetic. The parent steroid, 21-hydroxy-5-beta-pregnane-3,20-dione, is almost insoluble in water; esterifying its 21-hydroxyl group with succinic acid and forming the sodium salt yields hydroxydione sodium succinate, a water-soluble prodrug that plasma esterases (enzymes that cleave ester bonds) hydrolyze in vivo to release the active steroid. Like later neurosteroid anesthetics such as alfaxalone, it produces hypnosis by acting as a positive allosteric modulator of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), without meaningful analgesic or classical hormonal activity. Although valued for a wide margin of cardiovascular and respiratory safety, its very slow onset and a high incidence of injection-site thrombophlebitis (painful inflammation and clotting of the vein) led to its abandonment, yet it remains historically pivotal as the origin of the entire field of steroid anesthesia.

reference

Anesthetic

Minaxolone

Minaxolone is a synthetic water-soluble aminosteroid (a steroid carrying a basic amino group) developed by Glaxo in the late 1970s as an intravenous general anaesthetic and a successor to Althesin. Structurally it is a 2-beta-ethoxy, 11-alpha-(dimethylamino) derivative of the neuroactive pregnane skeleton, and it acts as a potent positive allosteric modulator at the neurosteroid recognition site of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), enhancing inhibitory conductance to produce hypnosis and surgical anaesthesia. Its basic amino group conferred solubility in water, avoiding the Cremophor EL vehicle (a polyethoxylated castor oil solubiliser) that made earlier lipophilic steroid anaesthetics prone to anaphylactoid reactions. After clinical trials conducted between roughly 1979 and 1982, its development was halted over toxicity and genotoxicity concerns arising in long-term rodent studies, and it was never marketed.

reference

Anesthetic

Org 20599

Org 20599 is a synthetic water-soluble aminosteroid general anaesthetic developed by Organon in the 1990s as a member of the 2-beta-morpholinyl pregnane class. Chemically it is (2beta,3alpha,5alpha)-21-chloro-3-hydroxy-2-(4-morpholinyl)pregnan-20-one, usually handled as its methanesulphonate (mesylate) salt, and it retains the 3-alpha-hydroxy, 5-alpha-reduced pregnane pharmacophore that defines the natural neurosteroid anaesthetics such as alphaxalone and allopregnanolone. Its principal action is positive allosteric modulation of the GABA-A receptor (the brain's main inhibitory chloride ion channel), with additional direct channel activation (GABA-mimetic agonism) at higher concentrations. It produced rapid-onset, short-duration anaesthesia in rodents but was never marketed; its close analogue Org 21465 reached Phase I human trials and caused excitatory involuntary movements in every volunteer, and the class was discontinued.

reference

Anesthetic

Org 21465

Org 21465 (also written ORG-21465) is a water-soluble aminosteroid intravenous anaesthetic developed by Organon in the 1990s as a companion candidate to the earlier compound Org 20599. It belongs to a series of 2-substituted (C2-morpholinyl) pregnane steroids engineered to combine the favourable receptor pharmacology of neuroactive steroids with the aqueous solubility needed for a practical injectable formulation, acting principally as a positive allosteric modulator (an agent that amplifies a receptor's response without being the primary trigger) of the GABA-A receptor (the brain's main inhibitory chloride ion channel). In computer-controlled infusion studies in healthy male volunteers the compound produced dose-related sedation and reversible loss of consciousness, but it was accompanied by prominent involuntary excitatory movements, injection-site venous pain, and slow equilibration with the effect site, and its clinical development was subsequently abandoned. It survives in the literature as a historical, niche illustration of the difficulty of translating neurosteroid GABA-A pharmacology into a usable anaesthetic.

reference

Anesthetic

Renanolone

Renanolone (3alpha-hydroxy-5beta-pregnane-11,20-dione) is a synthetic pregnane steroid that was investigated as an intravenous general anaesthetic during the Glaxo steroid-anaesthetic program of the 1960s and 1970s. It is the 5beta-configured epimer of alphaxalone (alfaxalone), differing only in the stereochemistry of the A/B ring fusion, and it belongs to the same 3alpha-hydroxy-pregnane pharmacophore that defines neurosteroid modulators of the GABA-A receptor (the brain's principal inhibitory chloride ion channel). Like other steroid anaesthetics it produces sedation, hypnosis and anaesthesia by acting as a positive allosteric modulator of GABA-A receptors, although modern photoaffinity work shows it occupies the intersubunit neurosteroid pocket roughly twenty times more weakly than its 5alpha counterpart. Never marketed, it survives as a historical and mechanistic reference compound within the neurosteroid anaesthetic class.

reference

NMDA Modulator

Traxoprodil

Traxoprodil (CP-101,606) started life at Pfizer in the 1990s as a stroke and traumatic-brain-injury neuroprotectant, built around a then-novel idea: block only the GluN2B (NR2B) subunit of the NMDA receptor instead of hammering the whole channel like PCP or MK-801. The stroke program stalled over QT-interval prolongation and hallucinations at neuroprotective doses, but the NR2B-selective mechanism looked too interesting to shelve. Pfizer repurposed it, and in a 2008 proof-of-concept study led by Sheldon Preskorn it relieved treatment-resistant major depression as an add-on therapy, one of the first solid human signals that NMDA blockade could work as an antidepressant outside of ketamine itself. But the same cardiac safety baggage that killed the stroke program followed it into psychiatry, and traxoprodil never advanced to Phase III for depression.

reference